nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—prostate cancer	0.171	0.397	CbGaD
Formoterol—ADRB2—prostate cancer	0.139	0.324	CbGaD
Formoterol—CYP2C19—prostate cancer	0.12	0.279	CbGaD
Formoterol—CYP2C19—Bicalutamide—prostate cancer	0.0401	0.128	CbGbCtD
Formoterol—CYP2C19—Nilutamide—prostate cancer	0.0401	0.128	CbGbCtD
Formoterol—CYP2C9—Bicalutamide—prostate cancer	0.0334	0.107	CbGbCtD
Formoterol—CYP2C9—Nilutamide—prostate cancer	0.0334	0.107	CbGbCtD
Formoterol—CYP2C19—Flutamide—prostate cancer	0.0332	0.106	CbGbCtD
Formoterol—CYP2D6—Bicalutamide—prostate cancer	0.0305	0.0975	CbGbCtD
Formoterol—CYP2D6—Abiraterone—prostate cancer	0.0253	0.0808	CbGbCtD
Formoterol—CYP2C9—Estrone—prostate cancer	0.02	0.0639	CbGbCtD
Formoterol—CYP2C9—Capecitabine—prostate cancer	0.0151	0.0484	CbGbCtD
Formoterol—CYP2C19—Estradiol—prostate cancer	0.0138	0.0441	CbGbCtD
Formoterol—CYP2C19—Prednisone—prostate cancer	0.0119	0.0379	CbGbCtD
Formoterol—CYP2C9—Estradiol—prostate cancer	0.0115	0.0367	CbGbCtD
Formoterol—CYP2D6—Doxorubicin—prostate cancer	0.00467	0.0149	CbGbCtD
Formoterol—Dobutamine—COMT—prostate cancer	0.000534	0.164	CrCbGaD
Formoterol—Arformoterol—CYP2A6—prostate cancer	0.000369	0.114	CrCbGaD
Formoterol—Fenoterol—ADRB2—prostate cancer	0.000332	0.102	CrCbGaD
Formoterol—Ritodrine—ADRB2—prostate cancer	0.000332	0.102	CrCbGaD
Formoterol—Arbutamine—ADRB2—prostate cancer	0.000311	0.0957	CrCbGaD
Formoterol—Arformoterol—ADRB2—prostate cancer	0.000302	0.0929	CrCbGaD
Formoterol—CYP2C19—urine—prostate cancer	0.000295	0.246	CbGeAlD
Formoterol—Dobutamine—ADRB2—prostate cancer	0.000286	0.0881	CrCbGaD
Formoterol—Arformoterol—CYP2C19—prostate cancer	0.00026	0.08	CrCbGaD
Formoterol—CYP2C9—urine—prostate cancer	0.000229	0.19	CbGeAlD
Formoterol—Labetalol—ADRB2—prostate cancer	0.00022	0.0679	CrCbGaD
Formoterol—CYP2D6—urine—prostate cancer	0.000172	0.143	CbGeAlD
Formoterol—CYP2A6—prostate gland—prostate cancer	0.000165	0.137	CbGeAlD
Formoterol—Isoprenaline—ADRB2—prostate cancer	0.000162	0.05	CrCbGaD
Formoterol—CYP2A6—seminal vesicle—prostate cancer	0.000139	0.116	CbGeAlD
Formoterol—Isoprenaline—CYP1A1—prostate cancer	0.000139	0.0428	CrCbGaD
Formoterol—ADRB1—prostate gland—prostate cancer	0.000132	0.11	CbGeAlD
Formoterol—CYP2D6—renal system—prostate cancer	4.21e-05	0.035	CbGeAlD
Formoterol—Infection—Docetaxel—prostate cancer	4.09e-05	0.000237	CcSEcCtD
Formoterol—Sinusitis—Epirubicin—prostate cancer	4.09e-05	0.000237	CcSEcCtD
Formoterol—Feeling abnormal—Etoposide—prostate cancer	4.09e-05	0.000236	CcSEcCtD
Formoterol—Hyperglycaemia—Doxorubicin—prostate cancer	4.08e-05	0.000236	CcSEcCtD
Formoterol—Diarrhoea—Mitoxantrone—prostate cancer	4.08e-05	0.000236	CcSEcCtD
Formoterol—Dry mouth—Capecitabine—prostate cancer	4.07e-05	0.000235	CcSEcCtD
Formoterol—Vomiting—Estradiol—prostate cancer	4.07e-05	0.000235	CcSEcCtD
Formoterol—Gastrointestinal pain—Etoposide—prostate cancer	4.05e-05	0.000235	CcSEcCtD
Formoterol—Nervous system disorder—Docetaxel—prostate cancer	4.04e-05	0.000234	CcSEcCtD
Formoterol—Ill-defined disorder—Prednisone—prostate cancer	4.04e-05	0.000234	CcSEcCtD
Formoterol—Rash—Estradiol—prostate cancer	4.03e-05	0.000233	CcSEcCtD
Formoterol—Dermatitis—Estradiol—prostate cancer	4.03e-05	0.000233	CcSEcCtD
Formoterol—Tachycardia—Docetaxel—prostate cancer	4.02e-05	0.000233	CcSEcCtD
Formoterol—Headache—Estradiol—prostate cancer	4.01e-05	0.000232	CcSEcCtD
Formoterol—Skin disorder—Docetaxel—prostate cancer	4e-05	0.000232	CcSEcCtD
Formoterol—Agitation—Prednisone—prostate cancer	4e-05	0.000231	CcSEcCtD
Formoterol—Oedema—Capecitabine—prostate cancer	3.99e-05	0.000231	CcSEcCtD
Formoterol—Angioedema—Prednisone—prostate cancer	3.98e-05	0.00023	CcSEcCtD
Formoterol—Infection—Capecitabine—prostate cancer	3.96e-05	0.000229	CcSEcCtD
Formoterol—Urticaria—Etoposide—prostate cancer	3.94e-05	0.000228	CcSEcCtD
Formoterol—Malaise—Prednisone—prostate cancer	3.93e-05	0.000227	CcSEcCtD
Formoterol—Rhinitis—Epirubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Formoterol—Body temperature increased—Etoposide—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Formoterol—Abdominal pain—Etoposide—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Formoterol—Conjunctivitis—Doxorubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Formoterol—Urinary tract infection—Doxorubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Formoterol—Nervous system disorder—Capecitabine—prostate cancer	3.91e-05	0.000226	CcSEcCtD
Formoterol—Tachycardia—Capecitabine—prostate cancer	3.89e-05	0.000225	CcSEcCtD
Formoterol—Pharyngitis—Epirubicin—prostate cancer	3.88e-05	0.000225	CcSEcCtD
Formoterol—Skin disorder—Capecitabine—prostate cancer	3.87e-05	0.000224	CcSEcCtD
Formoterol—Urinary tract disorder—Epirubicin—prostate cancer	3.86e-05	0.000223	CcSEcCtD
Formoterol—Oedema peripheral—Epirubicin—prostate cancer	3.85e-05	0.000223	CcSEcCtD
Formoterol—Hypotension—Docetaxel—prostate cancer	3.85e-05	0.000223	CcSEcCtD
Formoterol—Haematuria—Doxorubicin—prostate cancer	3.84e-05	0.000222	CcSEcCtD
Formoterol—Connective tissue disorder—Epirubicin—prostate cancer	3.84e-05	0.000222	CcSEcCtD
Formoterol—Urethral disorder—Epirubicin—prostate cancer	3.83e-05	0.000222	CcSEcCtD
Formoterol—Nausea—Estradiol—prostate cancer	3.8e-05	0.00022	CcSEcCtD
Formoterol—Vomiting—Mitoxantrone—prostate cancer	3.79e-05	0.000219	CcSEcCtD
Formoterol—Sinusitis—Doxorubicin—prostate cancer	3.78e-05	0.000219	CcSEcCtD
Formoterol—Visual impairment—Epirubicin—prostate cancer	3.77e-05	0.000218	CcSEcCtD
Formoterol—Hypertension—Prednisone—prostate cancer	3.76e-05	0.000217	CcSEcCtD
Formoterol—Rash—Mitoxantrone—prostate cancer	3.76e-05	0.000217	CcSEcCtD
Formoterol—Dermatitis—Mitoxantrone—prostate cancer	3.75e-05	0.000217	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.75e-05	0.000217	CcSEcCtD
Formoterol—Headache—Mitoxantrone—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Formoterol—Hypotension—Capecitabine—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Formoterol—Insomnia—Docetaxel—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Formoterol—Myalgia—Prednisone—prostate cancer	3.71e-05	0.000214	CcSEcCtD
Formoterol—Arthralgia—Prednisone—prostate cancer	3.71e-05	0.000214	CcSEcCtD
Formoterol—Anxiety—Prednisone—prostate cancer	3.69e-05	0.000214	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.68e-05	0.000213	CcSEcCtD
Formoterol—Dyspnoea—Docetaxel—prostate cancer	3.67e-05	0.000213	CcSEcCtD
Formoterol—Somnolence—Docetaxel—prostate cancer	3.66e-05	0.000212	CcSEcCtD
Formoterol—Discomfort—Prednisone—prostate cancer	3.66e-05	0.000212	CcSEcCtD
Formoterol—Hypersensitivity—Etoposide—prostate cancer	3.65e-05	0.000211	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Formoterol—Cardiac disorder—Epirubicin—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Formoterol—Rhinitis—Doxorubicin—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Formoterol—Dyspepsia—Docetaxel—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Formoterol—Insomnia—Capecitabine—prostate cancer	3.61e-05	0.000209	CcSEcCtD
Formoterol—Pharyngitis—Doxorubicin—prostate cancer	3.59e-05	0.000208	CcSEcCtD
Formoterol—Urinary tract disorder—Doxorubicin—prostate cancer	3.57e-05	0.000207	CcSEcCtD
Formoterol—Oedema peripheral—Doxorubicin—prostate cancer	3.57e-05	0.000206	CcSEcCtD
Formoterol—Gastrointestinal disorder—Docetaxel—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Formoterol—Asthenia—Etoposide—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Formoterol—Connective tissue disorder—Doxorubicin—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Formoterol—Dyspnoea—Capecitabine—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Formoterol—Oedema—Prednisone—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Formoterol—Anaphylactic shock—Prednisone—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Formoterol—Fatigue—Docetaxel—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Formoterol—Urethral disorder—Doxorubicin—prostate cancer	3.55e-05	0.000205	CcSEcCtD
Formoterol—Nausea—Mitoxantrone—prostate cancer	3.54e-05	0.000205	CcSEcCtD
Formoterol—Immune system disorder—Epirubicin—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Formoterol—Infection—Prednisone—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Formoterol—Mediastinal disorder—Epirubicin—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Formoterol—Constipation—Docetaxel—prostate cancer	3.52e-05	0.000204	CcSEcCtD
Formoterol—Pain—Docetaxel—prostate cancer	3.52e-05	0.000204	CcSEcCtD
Formoterol—Dyspepsia—Capecitabine—prostate cancer	3.51e-05	0.000203	CcSEcCtD
Formoterol—Pruritus—Etoposide—prostate cancer	3.51e-05	0.000203	CcSEcCtD
Formoterol—Arrhythmia—Epirubicin—prostate cancer	3.49e-05	0.000202	CcSEcCtD
Formoterol—Visual impairment—Doxorubicin—prostate cancer	3.49e-05	0.000202	CcSEcCtD
Formoterol—Nervous system disorder—Prednisone—prostate cancer	3.48e-05	0.000202	CcSEcCtD
Formoterol—Tachycardia—Prednisone—prostate cancer	3.47e-05	0.000201	CcSEcCtD
Formoterol—Skin disorder—Prednisone—prostate cancer	3.45e-05	0.0002	CcSEcCtD
Formoterol—Gastrointestinal disorder—Capecitabine—prostate cancer	3.44e-05	0.000199	CcSEcCtD
Formoterol—Fatigue—Capecitabine—prostate cancer	3.44e-05	0.000199	CcSEcCtD
Formoterol—Mental disorder—Epirubicin—prostate cancer	3.43e-05	0.000198	CcSEcCtD
Formoterol—Pain—Capecitabine—prostate cancer	3.41e-05	0.000197	CcSEcCtD
Formoterol—Constipation—Capecitabine—prostate cancer	3.41e-05	0.000197	CcSEcCtD
Formoterol—Malnutrition—Epirubicin—prostate cancer	3.4e-05	0.000197	CcSEcCtD
Formoterol—Feeling abnormal—Docetaxel—prostate cancer	3.4e-05	0.000196	CcSEcCtD
Formoterol—Diarrhoea—Etoposide—prostate cancer	3.39e-05	0.000196	CcSEcCtD
Formoterol—Gastrointestinal pain—Docetaxel—prostate cancer	3.37e-05	0.000195	CcSEcCtD
Formoterol—Cardiac disorder—Doxorubicin—prostate cancer	3.36e-05	0.000194	CcSEcCtD
Formoterol—Tension—Epirubicin—prostate cancer	3.34e-05	0.000193	CcSEcCtD
Formoterol—Dysgeusia—Epirubicin—prostate cancer	3.33e-05	0.000193	CcSEcCtD
Formoterol—Nervousness—Epirubicin—prostate cancer	3.31e-05	0.000191	CcSEcCtD
Formoterol—Back pain—Epirubicin—prostate cancer	3.29e-05	0.000191	CcSEcCtD
Formoterol—Feeling abnormal—Capecitabine—prostate cancer	3.29e-05	0.00019	CcSEcCtD
Formoterol—Dizziness—Etoposide—prostate cancer	3.28e-05	0.00019	CcSEcCtD
Formoterol—Muscle spasms—Epirubicin—prostate cancer	3.27e-05	0.000189	CcSEcCtD
Formoterol—Immune system disorder—Doxorubicin—prostate cancer	3.27e-05	0.000189	CcSEcCtD
Formoterol—Gastrointestinal pain—Capecitabine—prostate cancer	3.26e-05	0.000189	CcSEcCtD
Formoterol—Mediastinal disorder—Doxorubicin—prostate cancer	3.26e-05	0.000189	CcSEcCtD
Formoterol—Abdominal pain—Docetaxel—prostate cancer	3.26e-05	0.000188	CcSEcCtD
Formoterol—Body temperature increased—Docetaxel—prostate cancer	3.26e-05	0.000188	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.24e-05	0.000187	CcSEcCtD
Formoterol—Arrhythmia—Doxorubicin—prostate cancer	3.23e-05	0.000187	CcSEcCtD
Formoterol—Insomnia—Prednisone—prostate cancer	3.21e-05	0.000186	CcSEcCtD
Formoterol—Mental disorder—Doxorubicin—prostate cancer	3.17e-05	0.000183	CcSEcCtD
Formoterol—Urticaria—Capecitabine—prostate cancer	3.17e-05	0.000183	CcSEcCtD
Formoterol—Ill-defined disorder—Epirubicin—prostate cancer	3.16e-05	0.000183	CcSEcCtD
Formoterol—Abdominal pain—Capecitabine—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Formoterol—Body temperature increased—Capecitabine—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Formoterol—Vomiting—Etoposide—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Formoterol—Malnutrition—Doxorubicin—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Formoterol—Agitation—Epirubicin—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Formoterol—Dyspepsia—Prednisone—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Formoterol—Rash—Etoposide—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Formoterol—Dermatitis—Etoposide—prostate cancer	3.12e-05	0.000181	CcSEcCtD
Formoterol—Headache—Etoposide—prostate cancer	3.11e-05	0.00018	CcSEcCtD
Formoterol—Tension—Doxorubicin—prostate cancer	3.09e-05	0.000179	CcSEcCtD
Formoterol—Dysgeusia—Doxorubicin—prostate cancer	3.09e-05	0.000179	CcSEcCtD
Formoterol—Malaise—Epirubicin—prostate cancer	3.07e-05	0.000178	CcSEcCtD
Formoterol—Fatigue—Prednisone—prostate cancer	3.06e-05	0.000177	CcSEcCtD
Formoterol—Nervousness—Doxorubicin—prostate cancer	3.06e-05	0.000177	CcSEcCtD
Formoterol—Back pain—Doxorubicin—prostate cancer	3.05e-05	0.000176	CcSEcCtD
Formoterol—Constipation—Prednisone—prostate cancer	3.04e-05	0.000176	CcSEcCtD
Formoterol—Hypersensitivity—Docetaxel—prostate cancer	3.04e-05	0.000176	CcSEcCtD
Formoterol—Muscle spasms—Doxorubicin—prostate cancer	3.03e-05	0.000175	CcSEcCtD
Formoterol—Palpitations—Epirubicin—prostate cancer	3.01e-05	0.000174	CcSEcCtD
Formoterol—Cough—Epirubicin—prostate cancer	2.97e-05	0.000172	CcSEcCtD
Formoterol—Asthenia—Docetaxel—prostate cancer	2.96e-05	0.000171	CcSEcCtD
Formoterol—Nausea—Etoposide—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Formoterol—Hypertension—Epirubicin—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Formoterol—Hypersensitivity—Capecitabine—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Formoterol—Feeling abnormal—Prednisone—prostate cancer	2.93e-05	0.000169	CcSEcCtD
Formoterol—Ill-defined disorder—Doxorubicin—prostate cancer	2.92e-05	0.000169	CcSEcCtD
Formoterol—Pruritus—Docetaxel—prostate cancer	2.91e-05	0.000169	CcSEcCtD
Formoterol—Gastrointestinal pain—Prednisone—prostate cancer	2.91e-05	0.000168	CcSEcCtD
Formoterol—Arthralgia—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Formoterol—Chest pain—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Formoterol—Myalgia—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Formoterol—Agitation—Doxorubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Formoterol—Anxiety—Epirubicin—prostate cancer	2.89e-05	0.000167	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.88e-05	0.000167	CcSEcCtD
Formoterol—Discomfort—Epirubicin—prostate cancer	2.86e-05	0.000166	CcSEcCtD
Formoterol—Asthenia—Capecitabine—prostate cancer	2.86e-05	0.000166	CcSEcCtD
Formoterol—Malaise—Doxorubicin—prostate cancer	2.84e-05	0.000164	CcSEcCtD
Formoterol—Dry mouth—Epirubicin—prostate cancer	2.84e-05	0.000164	CcSEcCtD
Formoterol—Urticaria—Prednisone—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Formoterol—Pruritus—Capecitabine—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Formoterol—Diarrhoea—Docetaxel—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Formoterol—Body temperature increased—Prednisone—prostate cancer	2.81e-05	0.000163	CcSEcCtD
Formoterol—Abdominal pain—Prednisone—prostate cancer	2.81e-05	0.000163	CcSEcCtD
Formoterol—Palpitations—Doxorubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Formoterol—Oedema—Epirubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Formoterol—Anaphylactic shock—Epirubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Formoterol—Infection—Epirubicin—prostate cancer	2.76e-05	0.00016	CcSEcCtD
Formoterol—Cough—Doxorubicin—prostate cancer	2.75e-05	0.000159	CcSEcCtD
Formoterol—Diarrhoea—Capecitabine—prostate cancer	2.73e-05	0.000158	CcSEcCtD
Formoterol—Nervous system disorder—Epirubicin—prostate cancer	2.73e-05	0.000158	CcSEcCtD
Formoterol—Dizziness—Docetaxel—prostate cancer	2.72e-05	0.000158	CcSEcCtD
Formoterol—Hypertension—Doxorubicin—prostate cancer	2.72e-05	0.000157	CcSEcCtD
Formoterol—CYP2D6—testis—prostate cancer	2.72e-05	0.0226	CbGeAlD
Formoterol—Tachycardia—Epirubicin—prostate cancer	2.71e-05	0.000157	CcSEcCtD
Formoterol—Skin disorder—Epirubicin—prostate cancer	2.7e-05	0.000156	CcSEcCtD
Formoterol—Chest pain—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Formoterol—Arthralgia—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Formoterol—Myalgia—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Formoterol—Anxiety—Doxorubicin—prostate cancer	2.67e-05	0.000155	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.66e-05	0.000154	CcSEcCtD
Formoterol—Discomfort—Doxorubicin—prostate cancer	2.65e-05	0.000153	CcSEcCtD
Formoterol—Dizziness—Capecitabine—prostate cancer	2.64e-05	0.000153	CcSEcCtD
Formoterol—Dry mouth—Doxorubicin—prostate cancer	2.62e-05	0.000152	CcSEcCtD
Formoterol—Vomiting—Docetaxel—prostate cancer	2.62e-05	0.000152	CcSEcCtD
Formoterol—Hypersensitivity—Prednisone—prostate cancer	2.62e-05	0.000151	CcSEcCtD
Formoterol—Rash—Docetaxel—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Formoterol—Hypotension—Epirubicin—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Formoterol—Dermatitis—Docetaxel—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Formoterol—Headache—Docetaxel—prostate cancer	2.58e-05	0.000149	CcSEcCtD
Formoterol—Oedema—Doxorubicin—prostate cancer	2.57e-05	0.000149	CcSEcCtD
Formoterol—Anaphylactic shock—Doxorubicin—prostate cancer	2.57e-05	0.000149	CcSEcCtD
Formoterol—Infection—Doxorubicin—prostate cancer	2.55e-05	0.000148	CcSEcCtD
Formoterol—Asthenia—Prednisone—prostate cancer	2.55e-05	0.000147	CcSEcCtD
Formoterol—Vomiting—Capecitabine—prostate cancer	2.54e-05	0.000147	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.53e-05	0.000146	CcSEcCtD
Formoterol—Nervous system disorder—Doxorubicin—prostate cancer	2.52e-05	0.000146	CcSEcCtD
Formoterol—Rash—Capecitabine—prostate cancer	2.52e-05	0.000146	CcSEcCtD
Formoterol—Pruritus—Prednisone—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Formoterol—Insomnia—Epirubicin—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Formoterol—Dermatitis—Capecitabine—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Formoterol—Tachycardia—Doxorubicin—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Formoterol—Headache—Capecitabine—prostate cancer	2.5e-05	0.000145	CcSEcCtD
Formoterol—Skin disorder—Doxorubicin—prostate cancer	2.5e-05	0.000145	CcSEcCtD
Formoterol—Dyspnoea—Epirubicin—prostate cancer	2.48e-05	0.000143	CcSEcCtD
Formoterol—Somnolence—Epirubicin—prostate cancer	2.47e-05	0.000143	CcSEcCtD
Formoterol—Nausea—Docetaxel—prostate cancer	2.45e-05	0.000142	CcSEcCtD
Formoterol—Dyspepsia—Epirubicin—prostate cancer	2.45e-05	0.000142	CcSEcCtD
Formoterol—Diarrhoea—Prednisone—prostate cancer	2.43e-05	0.000141	CcSEcCtD
Formoterol—Hypotension—Doxorubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Formoterol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Formoterol—Fatigue—Epirubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Formoterol—Constipation—Epirubicin—prostate cancer	2.38e-05	0.000137	CcSEcCtD
Formoterol—Pain—Epirubicin—prostate cancer	2.38e-05	0.000137	CcSEcCtD
Formoterol—Nausea—Capecitabine—prostate cancer	2.37e-05	0.000137	CcSEcCtD
Formoterol—Dizziness—Prednisone—prostate cancer	2.35e-05	0.000136	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.34e-05	0.000136	CcSEcCtD
Formoterol—Insomnia—Doxorubicin—prostate cancer	2.33e-05	0.000135	CcSEcCtD
Formoterol—Dyspnoea—Doxorubicin—prostate cancer	2.29e-05	0.000133	CcSEcCtD
Formoterol—Feeling abnormal—Epirubicin—prostate cancer	2.29e-05	0.000132	CcSEcCtD
Formoterol—Somnolence—Doxorubicin—prostate cancer	2.29e-05	0.000132	CcSEcCtD
Formoterol—Gastrointestinal pain—Epirubicin—prostate cancer	2.27e-05	0.000131	CcSEcCtD
Formoterol—Dyspepsia—Doxorubicin—prostate cancer	2.26e-05	0.000131	CcSEcCtD
Formoterol—Vomiting—Prednisone—prostate cancer	2.26e-05	0.000131	CcSEcCtD
Formoterol—Rash—Prednisone—prostate cancer	2.24e-05	0.00013	CcSEcCtD
Formoterol—Dermatitis—Prednisone—prostate cancer	2.24e-05	0.00013	CcSEcCtD
Formoterol—Headache—Prednisone—prostate cancer	2.23e-05	0.000129	CcSEcCtD
Formoterol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.22e-05	0.000128	CcSEcCtD
Formoterol—Fatigue—Doxorubicin—prostate cancer	2.22e-05	0.000128	CcSEcCtD
Formoterol—Urticaria—Epirubicin—prostate cancer	2.21e-05	0.000128	CcSEcCtD
Formoterol—Pain—Doxorubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Formoterol—Constipation—Doxorubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Formoterol—Abdominal pain—Epirubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Formoterol—Body temperature increased—Epirubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Formoterol—Feeling abnormal—Doxorubicin—prostate cancer	2.12e-05	0.000123	CcSEcCtD
Formoterol—Nausea—Prednisone—prostate cancer	2.11e-05	0.000122	CcSEcCtD
Formoterol—Gastrointestinal pain—Doxorubicin—prostate cancer	2.1e-05	0.000122	CcSEcCtD
Formoterol—Hypersensitivity—Epirubicin—prostate cancer	2.05e-05	0.000118	CcSEcCtD
Formoterol—Urticaria—Doxorubicin—prostate cancer	2.04e-05	0.000118	CcSEcCtD
Formoterol—Abdominal pain—Doxorubicin—prostate cancer	2.03e-05	0.000118	CcSEcCtD
Formoterol—Body temperature increased—Doxorubicin—prostate cancer	2.03e-05	0.000118	CcSEcCtD
Formoterol—Asthenia—Epirubicin—prostate cancer	1.99e-05	0.000115	CcSEcCtD
Formoterol—Pruritus—Epirubicin—prostate cancer	1.97e-05	0.000114	CcSEcCtD
Formoterol—Diarrhoea—Epirubicin—prostate cancer	1.9e-05	0.00011	CcSEcCtD
Formoterol—Hypersensitivity—Doxorubicin—prostate cancer	1.89e-05	0.00011	CcSEcCtD
Formoterol—Asthenia—Doxorubicin—prostate cancer	1.84e-05	0.000107	CcSEcCtD
Formoterol—Dizziness—Epirubicin—prostate cancer	1.84e-05	0.000106	CcSEcCtD
Formoterol—Pruritus—Doxorubicin—prostate cancer	1.82e-05	0.000105	CcSEcCtD
Formoterol—Vomiting—Epirubicin—prostate cancer	1.77e-05	0.000102	CcSEcCtD
Formoterol—Diarrhoea—Doxorubicin—prostate cancer	1.76e-05	0.000102	CcSEcCtD
Formoterol—Rash—Epirubicin—prostate cancer	1.75e-05	0.000101	CcSEcCtD
Formoterol—Dermatitis—Epirubicin—prostate cancer	1.75e-05	0.000101	CcSEcCtD
Formoterol—Headache—Epirubicin—prostate cancer	1.74e-05	0.000101	CcSEcCtD
Formoterol—Dizziness—Doxorubicin—prostate cancer	1.7e-05	9.84e-05	CcSEcCtD
Formoterol—Nausea—Epirubicin—prostate cancer	1.65e-05	9.55e-05	CcSEcCtD
Formoterol—Vomiting—Doxorubicin—prostate cancer	1.63e-05	9.46e-05	CcSEcCtD
Formoterol—Rash—Doxorubicin—prostate cancer	1.62e-05	9.38e-05	CcSEcCtD
Formoterol—Dermatitis—Doxorubicin—prostate cancer	1.62e-05	9.37e-05	CcSEcCtD
Formoterol—Headache—Doxorubicin—prostate cancer	1.61e-05	9.32e-05	CcSEcCtD
Formoterol—Nausea—Doxorubicin—prostate cancer	1.53e-05	8.84e-05	CcSEcCtD
Formoterol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	5.03e-06	6.32e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	5.02e-06	6.31e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—MTHFR—prostate cancer	5.01e-06	6.29e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ACHE—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTT1—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	4.98e-06	6.26e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTT1—prostate cancer	4.95e-06	6.21e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ACHE—prostate cancer	4.95e-06	6.21e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP2A6—prostate cancer	4.93e-06	6.2e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PPARA—prostate cancer	4.92e-06	6.17e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	4.91e-06	6.17e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NCOA2—prostate cancer	4.9e-06	6.15e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP2A6—prostate cancer	4.89e-06	6.14e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	4.88e-06	6.13e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	4.87e-06	6.12e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.87e-06	6.12e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—prostate cancer	4.8e-06	6.03e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKR1C3—prostate cancer	4.8e-06	6.03e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TERT—prostate cancer	4.78e-06	6.01e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PRKACB—prostate cancer	4.77e-06	5.99e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKR1C3—prostate cancer	4.76e-06	5.97e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PRKACB—prostate cancer	4.73e-06	5.94e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP17A1—prostate cancer	4.72e-06	5.93e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—prostate cancer	4.7e-06	5.9e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP17A1—prostate cancer	4.68e-06	5.88e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TERT—prostate cancer	4.68e-06	5.87e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC5A5—prostate cancer	4.67e-06	5.86e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CAV1—prostate cancer	4.62e-06	5.8e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.62e-06	5.8e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	4.57e-06	5.74e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP2E1—prostate cancer	4.56e-06	5.73e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NQO1—prostate cancer	4.51e-06	5.66e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOA2—prostate cancer	4.5e-06	5.65e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	4.47e-06	5.62e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—LEP—prostate cancer	4.47e-06	5.61e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOA2—prostate cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TH—prostate cancer	4.44e-06	5.58e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CAV1—prostate cancer	4.42e-06	5.56e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.42e-06	5.55e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP3A4—prostate cancer	4.4e-06	5.52e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.38e-06	5.49e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KDR—prostate cancer	4.37e-06	5.49e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—LEP—prostate cancer	4.37e-06	5.48e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CAV1—prostate cancer	4.33e-06	5.43e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1B1—prostate cancer	4.32e-06	5.43e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.3e-06	5.39e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KDR—prostate cancer	4.28e-06	5.37e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ESR1—prostate cancer	4.26e-06	5.35e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.26e-06	5.35e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CG—prostate cancer	4.21e-06	5.29e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP2E1—prostate cancer	4.2e-06	5.27e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GGT1—prostate cancer	4.19e-06	5.26e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ESR1—prostate cancer	4.17e-06	5.24e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BAD—prostate cancer	4.16e-06	5.22e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.16e-06	5.22e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NQO1—prostate cancer	4.15e-06	5.21e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NCOA1—prostate cancer	4.12e-06	5.18e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NQO1—prostate cancer	4.11e-06	5.16e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TH—prostate cancer	4.09e-06	5.13e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BAD—prostate cancer	4.07e-06	5.11e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP19A1—prostate cancer	4.07e-06	5.1e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TH—prostate cancer	4.05e-06	5.09e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.05e-06	5.08e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—APC—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP3A4—prostate cancer	4.01e-06	5.04e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.99e-06	5.01e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—INS—prostate cancer	3.99e-06	5e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IRS1—prostate cancer	3.98e-06	5e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGF—prostate cancer	3.98e-06	5e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.98e-06	4.99e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—APC—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—RXRA—prostate cancer	3.92e-06	4.93e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CREBBP—prostate cancer	3.9e-06	4.9e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGF—prostate cancer	3.9e-06	4.89e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IRS1—prostate cancer	3.9e-06	4.89e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	3.87e-06	4.86e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GGT1—prostate cancer	3.85e-06	4.84e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GGT1—prostate cancer	3.82e-06	4.79e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.82e-06	4.79e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—INS—prostate cancer	3.81e-06	4.79e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOA1—prostate cancer	3.79e-06	4.76e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	3.78e-06	4.75e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—COMT—prostate cancer	3.78e-06	4.75e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTP1—prostate cancer	3.76e-06	4.72e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOA1—prostate cancer	3.76e-06	4.72e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP19A1—prostate cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	3.74e-06	4.69e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—INS—prostate cancer	3.73e-06	4.69e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP19A1—prostate cancer	3.71e-06	4.65e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ITPR1—prostate cancer	3.7e-06	4.65e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CD—prostate cancer	3.7e-06	4.65e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1—prostate cancer	3.69e-06	4.63e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	3.67e-06	4.61e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	3.65e-06	4.59e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.64e-06	4.57e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1—prostate cancer	3.61e-06	4.53e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—RXRA—prostate cancer	3.61e-06	4.53e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	3.59e-06	4.51e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—RXRA—prostate cancer	3.58e-06	4.49e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	3.57e-06	4.48e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	3.54e-06	4.45e-05	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	3.51e-06	4.41e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	3.5e-06	4.4e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TYMS—prostate cancer	3.5e-06	4.39e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NOS3—prostate cancer	3.49e-06	4.39e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	3.49e-06	4.38e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.48e-06	4.37e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—COMT—prostate cancer	3.48e-06	4.37e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	3.47e-06	4.35e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	3.47e-06	4.35e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTP1—prostate cancer	3.46e-06	4.34e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTM1—prostate cancer	3.46e-06	4.34e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—COMT—prostate cancer	3.45e-06	4.33e-05	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	3.43e-06	4.31e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTP1—prostate cancer	3.43e-06	4.31e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	3.43e-06	4.3e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ITPR1—prostate cancer	3.4e-06	4.27e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—LPL—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF2—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ITPR1—prostate cancer	3.37e-06	4.24e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOS3—prostate cancer	3.35e-06	4.2e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.32e-06	4.17e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF2—prostate cancer	3.32e-06	4.17e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.28e-06	4.11e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOS3—prostate cancer	3.27e-06	4.11e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JAK2—prostate cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ERCC2—prostate cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CB—prostate cancer	3.23e-06	4.05e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TYMS—prostate cancer	3.22e-06	4.04e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—prostate cancer	3.2e-06	4.01e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TYMS—prostate cancer	3.19e-06	4e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	3.19e-06	4e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTM1—prostate cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MDM2—prostate cancer	3.17e-06	3.99e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTM1—prostate cancer	3.15e-06	3.96e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	3.13e-06	3.93e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—LPL—prostate cancer	3.12e-06	3.92e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3.12e-06	3.91e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MDM2—prostate cancer	3.1e-06	3.9e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—LPL—prostate cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	3.06e-06	3.84e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—MTHFR—prostate cancer	3.05e-06	3.84e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	3.02e-06	3.79e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.01e-06	3.78e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPARA—prostate cancer	3e-06	3.76e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ERCC2—prostate cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	2.97e-06	3.73e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ERCC2—prostate cancer	2.96e-06	3.72e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	2.9e-06	3.64e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	2.9e-06	3.64e-05	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	2.87e-06	3.6e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CASP3—prostate cancer	2.84e-06	3.57e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—prostate cancer	2.84e-06	3.56e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	2.83e-06	3.56e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—prostate cancer	2.82e-06	3.54e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CAV1—prostate cancer	2.82e-06	3.54e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MTHFR—prostate cancer	2.81e-06	3.53e-05	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	2.8e-06	3.52e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTEN—prostate cancer	2.79e-06	3.5e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MTHFR—prostate cancer	2.79e-06	3.5e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CASP3—prostate cancer	2.78e-06	3.49e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—prostate cancer	2.77e-06	3.48e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—prostate cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—prostate cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPARA—prostate cancer	2.76e-06	3.46e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	2.74e-06	3.44e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPARA—prostate cancer	2.73e-06	3.43e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—prostate cancer	2.7e-06	3.4e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.69e-06	3.38e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MMP9—prostate cancer	2.68e-06	3.37e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	2.68e-06	3.36e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTEN—prostate cancer	2.67e-06	3.35e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—EP300—prostate cancer	2.66e-06	3.34e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MMP9—prostate cancer	2.63e-06	3.3e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	2.62e-06	3.28e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTEN—prostate cancer	2.61e-06	3.28e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	2.6e-06	3.27e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CAV1—prostate cancer	2.59e-06	3.25e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CAV1—prostate cancer	2.57e-06	3.23e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.57e-06	3.22e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	2.55e-06	3.2e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EP300—prostate cancer	2.54e-06	3.2e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EP300—prostate cancer	2.49e-06	3.13e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SRC—prostate cancer	2.47e-06	3.11e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.45e-06	3.08e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—INS—prostate cancer	2.43e-06	3.05e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.42e-06	3.04e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.39e-06	3e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CREBBP—prostate cancer	2.38e-06	2.99e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.36e-06	2.96e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.36e-06	2.96e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.34e-06	2.94e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.33e-06	2.93e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.26e-06	2.83e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—INS—prostate cancer	2.23e-06	2.81e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—prostate cancer	2.22e-06	2.78e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—INS—prostate cancer	2.22e-06	2.78e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.21e-06	2.78e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CREBBP—prostate cancer	2.19e-06	2.75e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CREBBP—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.16e-06	2.72e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NOS3—prostate cancer	2.13e-06	2.68e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.12e-06	2.66e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.08e-06	2.61e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.06e-06	2.58e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.05e-06	2.57e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2e-06	2.52e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.97e-06	2.47e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CA—prostate cancer	1.97e-06	2.47e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NOS3—prostate cancer	1.96e-06	2.46e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—prostate cancer	1.95e-06	2.45e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NOS3—prostate cancer	1.94e-06	2.44e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	1.88e-06	2.36e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	1.84e-06	2.31e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—prostate cancer	1.82e-06	2.29e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.81e-06	2.27e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—prostate cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—prostate cancer	1.78e-06	2.24e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—prostate cancer	1.78e-06	2.23e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTEN—prostate cancer	1.7e-06	2.13e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—prostate cancer	1.67e-06	2.09e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—prostate cancer	1.63e-06	2.05e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—EP300—prostate cancer	1.62e-06	2.04e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—AKT1—prostate cancer	1.61e-06	2.02e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTEN—prostate cancer	1.56e-06	1.96e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTEN—prostate cancer	1.55e-06	1.95e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.54e-06	1.93e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.5e-06	1.89e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—EP300—prostate cancer	1.49e-06	1.87e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—EP300—prostate cancer	1.48e-06	1.86e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.2e-06	1.51e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.1e-06	1.38e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.09e-06	1.37e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKT1—prostate cancer	9.79e-07	1.23e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKT1—prostate cancer	9.01e-07	1.13e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKT1—prostate cancer	8.93e-07	1.12e-05	CbGpPWpGaD
